fashion -WSS

fashion

author：leisure time 2025-09-27 12:58:07 - browse：7

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： RaDonda Vaught links Vanderbilt hospital issues to patient death

leisure time

WSS

HHS secretary Becerra pressed on Change HealthCare cyberattack

First U.S. drug developed to treat liver disease MASH is approved

Using force crossed my mind when examining a defiant young patient

FDA advisers back CAR

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Medicare Advantage isn’t working — for anyone

entertainment

fashion

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

As demand for Covid shots wanes, Moderna seeks its next success

Virtual repurposing can help discover new uses for existing drugs

New air purifier tech could be key to improving indoor air quality

Cholera vaccine supplies dangerously low, outbreaks surging

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CDC advisory group OKs chikungunya vaccine

Guidelines to prevent youth baseball injuries need more muscle

Steward Health Care Massachusetts hospitals face fiscal disaster

hotspot

HHS secretary Becerra pressed on Change HealthCare cyberattack

Redefining sustainability for the pharmaceutical industry

First U.S. drug developed to treat liver disease MASH is approved

Pushing for an NIH office for post

EPA limits use of carcinogenic gas for sterilizing medical devices

Amid AI frenzy, a top HHS official's quest to create safeguards

leisure time

leisure time

entertainment

focus